Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING therapy. This study will investigate the safety, biodistribution and potential usefulness of a novel 68Ga-labeled agonist (\[68Ga\]Ga-Sa-DABI-4) for noninvasive positron emission tomography (PET) imaging of STING expression in the tumor microenvironment.
At least 18 years of age.
Signed informed consent.
Patients with suspected or newly diagnosed or previously malignant disease.
Patients with non-malignant disease.
Patients with pregnancy.
The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Known or expected hypersensitivity to [68Ga]Ga-Sa-DABI-4 or any of its components.
Single group
[68Ga]Ga-Sa-DABI-4
DrugEach subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.
Diagnostic efficacy
The sensitivity, specificity, and accuracy of \[68Ga\]Ga-Sa-DABI-4 PET
Click on the lead sponsor to view all of their trials.
